Josh Jennings, an analyst from TD Cowen, reiterated the Buy rating on Insulet. The associated price target remains the same with $379.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Josh Jennings has given his Buy rating due to a combination of factors that highlight Insulet’s promising growth trajectory. Despite a recent drop in share price, Jennings believes the company’s investor day effectively communicated its strong potential for both near- and long-term expansion. Insulet projects a robust 20% compound annual growth rate in sales through 2028, driven by the ongoing adoption of its Omnipod system and expansion into new markets.
Furthermore, the company anticipates an increase in its adjusted operating margin by about 100 basis points annually, alongside a projected earnings per share growth of 25% or more from 2025 to 2028. Insulet’s commitment to innovation is underscored by its plan to invest over $1 billion in research and development over the next three years. The company also expects its free cash flow to remain strong, supporting continued reinvestment in innovation and global expansion. Jennings’s confidence is bolstered by the anticipated growth in market penetration for both type 1 and type 2 automated insulin delivery systems, both in the US and internationally.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $380.00 price target.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PODD in relation to earlier this year.